CCM Duopharma Biotech Berhad (Duopharma) is a Malaysian-based investment holding company. We are public-listed on the Main Board of Bursa Malaysia with Permodalan Nasional Berhad (PNB) as our major shareholder. Duopharma has grown to being one of the top 20 Government-Linked Companies (GLCs) and also a Bumiputra Corporate Public Listed Company (BCPLC) under an initiative by the Ministry of International Trade and Industry (MITI). We are the No. 1 pharmaceutical company in Malaysia and we aspire to become one of the leading pharmaceutical companies in ASEAN by 2022.
Our activities are centred on developing, manufacturing and marketing generic drugs and branded pharmaceutical products. We produce more than 200 generic drugs, including our award-winning medications such as Omesec and Vascor and also over-the-counter brands such as Champs, Proviton, Flavettes and Naturalle. We are expanding our portfolio of ethical and OTC products to include niche products in the therapeutic areas of oncology, biosimilars and vaccines.
We are the first pharmaceutical company to obtain the world’s 1st Halal Pharmaceutical Certification based on MS 2424 in 2013. We are also awarded the Pharmaceutical Company of the Year by Frost and Sullivan for 2013, 2016 and 2017 under the Generics Drugs Category, and the Islamic Economy Award for the Food and Health Category during the Global Islamic Economy Summit 2015 in Dubai.
We also have a regional presence with a network of offices in Singapore, Indonesia and the Philippines in our bid to expand our horizon and avail our products to more than 30 countries. Our products and services meet stringent and consistent compliance procedures implemented throughout CCM Duopharma Biotech group of companies to meet the growing needs of the domestic and overseas markets.